ESTRO 2024 - Abstract Book

S4720

Physics - Optimisation, algorithms and applications for ion beam treatment planning

ESTR0 2024

Conclusion:

The increase in adaptation rate at lower robustness levels and the benefit to the patient in the form of OAR dose sparing and gains in NTCP values were expected. The lowered risk of post treatment toxicities at lower robustness levels is clinically relevant, particularly in cases where meeting our clinical goals is not compromised by having a dose that is more conformal to the target. This is essential for estimating the trade-off between plan robustness and adaptation rate for proton therapy of lung cancer patients and ultimately improving the treatment workflow both from the perspective of the patients’ post-treatment quality-of-life and reducing the medical personnel’s need for unnecessary image acquisition and manual replanning.